Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (626)	2/16/2000 11:08:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

John, According to my Marketguide figures, AMGN's market cap (essentially based on two products) now slightly exceeds that of such pharma giants as LLY, AHP, SGP and SBH. I'll post the current market caps in the following post. Peter

To: John Metcalf who wrote (626)	2/16/2000 11:12:00 PM
From: Biomaven	Read Replies (4) \| Respond to of 52153

Market caps > $100 million. Symbol Market Capitalization MRK $153,101 PFE $130,655 BMY $126,088 JNJ $110,984 GLX $85,657 WLA $78,353 AMGN $71,378 LLY $66,794 AHP $61,614 SGP $60,232 SBH $59,230 ABT $52,800 DNA $43,008 AZN $33,127 IMNX $28,079 PNU $26,443 NYE $19,416 BGEN $16,160 CAH $12,711 MEDI $11,469 ELN $9,819 MLNM $9,662 NVO $9,014 HGSI $8,698 CHIR $8,186 AGN $8,105 CRA $7,584 AFFX $7,001 INCY $6,175 SEPR $5,327 IDPH $5,156 ABGX $5,008 GENZ $4,454 QGENF $4,408 QLTI $4,351 CMDX $4,119 BVF $4,105 PDLI $3,821 WPI $3,767 AZA $3,728 IVX $3,680 ALKS $3,557 TLRK $3,446 CRGN $3,069 MEDX $3,068 JMED $3,021 MYL $3,021 BCHE $2,942 GILD $2,811 CELG $2,774 IMCL $2,377 ADRX $2,230 CEPH $2,191 SHPGY $2,147 GLGC $2,033 KING $1,944 ICN $1,807 MKG $1,804 IVGN $1,730 ICOS $1,641 ENZN $1,638 TECH $1,532 DGX $1,520 MRX $1,402 VRTX $1,385 SUPG $1,366 CORR $1,358 MYGN $1,314 ALXN $1,310 CLPA $1,248 VPHM $1,148 PCOP $1,130 CYTO $1,126 IMMU $1,108 GENXY $1,072 ABSC $1,056 PCYC $1,038 BRL $1,013 VICL $1,008 PGNX $988 LGND $987 TKTX $961 VIRS $949 NBTY $937 BTGC $936 RXSD $931 ALO $929 CEGE $927 ILXO $921 TTP $919 CVTX $911 CRXA $909 CVD $901 LYNX $871 ENMD $853 EMIS $835 AVGN $833 CAR $821 AAS $819 GZTC $798 GENE $793 GERN $792 GLFD $755 AMLN $753 CBST $745 IDXX $740 MMP $704 CLTR $678 TGEN $672 SANG $671 PHCC $670 NBIX $668 DURA $663 AMRI $652 BXM $645 ALLP $642 PHGN $635 PRGO $621 VGIN $619 AVIR $582 BDY $542 PGNS $539 BIOM $525 XOMA $521 APHT $518 NRGN $517 OSIP $515 TXB $514 PLMD $503 KV.B $503 GNLB $480 CNTBY $479 REGN $478 CERS $472 MRVT $468 LIPO $467 BCRX $466 TRGNY $465 MOGN $456 CBMI $445 AXPH $441 VLTS $439 IMGN $437 DIGE $436 ATIS $426 AVAN $423 PPDI $419 ORG $417 ARQL $398 SHP $392 NOVN $390 CNCT $373 TCLN $371 GELX $369 TGX $349 ISIP $344 ARIA $342 CLTX $339 NEXL $339 DUSA $336 PRXL $335 BSTE $330 RZYM $323 AVII $323 LJLB $318 CTIC $316 BBIOY $316 ALGO $302 NEO $302 SCIO $289 NABI $288 KOSP $287 MATX $283 DRMD $282 VION $280 MRE $279 IMNR $279 NTEC $274 SCOR $274 CHRX $272 CVAS $267 HEB $264 NPSP $262 ONXX $245 HQL $245 SAFS $243 GZMO $239 COB $230 NFLD $226 DCRN $224 NSTA $219 OXGN $216 SCLN $215 GNTA $210 BCII $205 CTRX $204 MCDE $203 WCRX $203 PPCO $200 MATK $200 IART $200 BIOI $198 GZSP $194 GLIA $193 INKP $193 VITX $191 PARS $190 RGEN $190 SERO $188 CIMA $186 EPIX $184 CHTT $181 NVX $177 HEPH $176 SNAP $168 CGPI $155 ZILA $155 CYPB $153 LJPC $153 NERX $152 KNDL $147 VVUS $145 TRGA $143 VYSI $143 AKRN $143 BLSI $140 NMPS $140 CYPH $139 MCHM $137 GZTR $137 PRX $137 KITS $134 BTRN $134 BIORY $133 NOX $129 ISV $128 SYBB $125 SNTKY $124 LCBM $123 HSKA $121 XNVA $118 MAGN $118 TRIBY $116 CTII $116 NPRO $115 ABAX $111 PMD $108 ATRX $107 SHM $106 NEOT $104 NASI $104 IPIC $104 AMBI $103 BLUD $101

To: John Metcalf who wrote (626)	2/16/2000 11:29:00 PM
From: Larry Liebman	Read Replies (1) \| Respond to of 52153

Continuing to happily hold. Continue to view lack of supply as a key to rapid appreciation. It also doesn't hurt that 5+ years of genomic research is coming to fruition as witnessed by daily news releases. Wondering what weird and wonderful biotech combinations may ultimatley become the new big pharma, i.e., MLNM and ABSC, CRA and GLGC, AFFX and INCY, HGSI and ABGX...Bio's are flexing their muscles...Still surprised big pharma didn't/hasn't picked off deep pipeline-into clinic bio like NBIX and ALXN. However, by no means complaining!